Blood Pressure-Lowering Antiemetic
Chlorpromazine is the antiemetic with documented blood pressure-lowering effects and can be used in hypertensive patients, though it should be reserved for specific clinical scenarios rather than routine antiemetic therapy.
Chlorpromazine as a Blood Pressure-Lowering Antiemetic
Mechanism and Clinical Evidence
Chlorpromazine possesses both antiemetic and antihypertensive properties through alpha-adrenergic blockade, making it unique among commonly used antiemetics 1, 2.
In hypertensive emergencies, parenteral chlorpromazine (25-50 mg intramuscularly followed by continuous IV infusion at 2-8 mg/h) reduced blood pressure from 200-330/120-200 mmHg to 100-150/60-100 mmHg within 1-3 hours 1.
A 5-year prospective study demonstrated that chlorpromazine combined with furosemide successfully treated acute severe hypertension (>225/130 mmHg) in 27 of 30 patients with a single administration, producing gradual but progressive blood pressure reduction over 4 hours 2.
Clinical Context and Positioning
NCCN guidelines list chlorpromazine among antiemetic options for low emetogenic chemotherapy regimens, though it is not a first-line agent 3.
For breakthrough chemotherapy-induced nausea/vomiting, phenothiazines including prochlorperazine (not chlorpromazine specifically) are recommended at doses of 25 mg suppository PR every 12 hours or 10 mg PO/IV every 6 hours 4.
Chlorpromazine is not mentioned in contemporary hypertension management guidelines as a standard antihypertensive agent, reflecting its limited role in routine blood pressure control 5, 6, 7.
Important Safety Considerations
Intracranial Pressure Concerns
In patients with intracranial hypertension, chlorpromazine reduced mean arterial blood pressure by 18-20% but raised intracranial pressure by 10-35% in those with moderately elevated ICP (20-40 mmHg) and by 38-64% in those with severely elevated ICP (>40 mmHg) 8.
Cerebral perfusion pressure decreased by 20-32% with moderate ICP elevation and 40-54% with severe ICP elevation following chlorpromazine administration 8.
This makes chlorpromazine contraindicated in patients with increased intracranial pressure or hemorrhagic stroke 9, 8.
Cardiac Safety Profile
Recent data from hemodialysis patients showed chlorpromazine had better cardiac safety compared to haloperidol, with lower 1-year risk of sudden cardiac death 10.
However, all typical antipsychotics including chlorpromazine carry risk for QT prolongation and should be used cautiously in patients with cardiac comorbidities 10.
Monitoring Requirements
Patients receiving chlorpromazine require monitoring for dystonic reactions, similar to other phenothiazines like prochlorperazine 3.
Diphenhydramine can be used to treat dystonic reactions; benztropine may be substituted in patients allergic to diphenhydramine 3.
Practical Clinical Algorithm
When to Consider Chlorpromazine
Hypertensive patient requiring antiemetic therapy who has:
Breakthrough nausea/vomiting in hypertensive patients when:
Absolute Contraindications
- Intracranial hypertension or hemorrhagic stroke 9, 8
- Severe cardiac conduction abnormalities or prolonged QT interval 10
Preferred Alternatives in Most Scenarios
For routine antiemetic prophylaxis in hypertensive patients, standard regimens (5-HT3 antagonists, NK1 antagonists, dexamethasone) do not adversely affect blood pressure and should be used preferentially 3, 4.
Metoclopramide and prochlorperazine are more commonly recommended phenothiazines for low-risk emetogenic therapy, though they lack significant antihypertensive effects 3.
Key Clinical Pitfall
Do not use chlorpromazine as a routine antiemetic simply because a patient has hypertension 3. The drug's antihypertensive effect is most relevant in acute hypertensive crises with concurrent nausea/vomiting 1, 2. For standard antiemetic prophylaxis in controlled hypertension, conventional antiemetic regimens are safer and better studied 3, 4.